Education
About Us
Working with TipRanks
Follow Us
Nuvation Bio Inc (NUVB)
NYSE:NUVB
NUVB Stock Chart & Stats
$5.84
-$0.19(-5.85%)
At close: 4:00 PM EST
$5.84
-$0.19(-5.85%)
Day’s Range― - ―
52-Week Range$1.54 - $9.75
Previous CloseN/A
Volume977.37K
Average Volume (3M)4.73M
Market Cap
$2.01B
Enterprise Value$1.27B
Total Cash (Recent Filing)$549.04M
Total Debt (Recent Filing)$57.55M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
May 19, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding342,833,440
10 Day Avg. Volume3,878,742
30 Day Avg. Volume4,728,901
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)10.01
Price to Sales (P/S)48.65
P/FCF Ratio0.00
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue47.47
Enterprise Value/Gross Profit87.49
Enterprise Value/Ebitda-5.91
Forecast
1Y Price Target
$12.00Price Target Upside105.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.38
Revenue Forecast (FY)$184.70M
Bulls Say, Bears Say
Bulls Say
Clinical Data UpdateManagement guided for a meaningful clinical data update from a single-arm study of safusidenib in high-grade oligodendroglioma, which could strengthen evidence of clinical benefit and drive investor interest.
Commercial Partnership And UptakeCommercial launch of Ibtrozi showed rapid patient adoption with sales in line with consensus, and an exclusive ex‑U.S. collaboration with Eisai expands commercialization reach and adds upfront, milestone and royalty upside.
Regulatory StrategyManagement intends to pursue an accelerated regulatory pathway with a focused registration trial for safusidenib, which could shorten the approval timeline and lower regulatory risk for the program.
Bears Say
Clinical And Commercial RiskPotential for negative clinical proof‑of‑concept results or weaker-than-expected commercial uptake versus competitors could limit revenue growth and valuation upside.
Pipeline DiscontinuationCompany discontinued development of NUV-1511 due to inconsistent efficacy across cohorts, representing a tangible pipeline setback and requiring resource reallocation.
Research Conflict Of InterestCovering firm conducts business with companies it covers, creating potential conflicts that could undermine perceived objectivity of published research and investor confidence.
Nuvation Bio News
NUVB FAQ
What was Nuvation Bio Inc’s price range in the past 12 months?
Nuvation Bio Inc lowest stock price was $1.54 and its highest was $9.75 in the past 12 months.
What is Nuvation Bio Inc’s market cap?
Nuvation Bio Inc’s market cap is $2.01B.
When is Nuvation Bio Inc’s upcoming earnings report date?
Nuvation Bio Inc’s upcoming earnings report date is May 19, 2026 which is in 76 days.
How were Nuvation Bio Inc’s earnings last quarter?
Nuvation Bio Inc released its earnings results on Mar 02, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.089 by -$0.021.
Is Nuvation Bio Inc overvalued?
According to Wall Street analysts Nuvation Bio Inc’s price is currently Undervalued.
Does Nuvation Bio Inc pay dividends?
Nuvation Bio Inc does not currently pay dividends.
What is Nuvation Bio Inc’s EPS estimate?
Nuvation Bio Inc’s EPS estimate is -0.09.
How many shares outstanding does Nuvation Bio Inc have?
Nuvation Bio Inc has 342,833,440 shares outstanding.
What happened to Nuvation Bio Inc’s price movement after its last earnings report?
Nuvation Bio Inc reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.089. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Nuvation Bio Inc?
Currently, no hedge funds are holding shares in NUVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvation Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (105.48% Upside)
$12.00 (105.48% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Bullish
Bullish news 79%
Bearish news 11%
Bearish news 11%
Technicals
SMA
Positive
20 days / 200 days
Momentum
196.44%
12-Months-Change
Fundamentals
Return on Equity
-52.49%
Trailing 12-Months
Asset Growth
5.25%
Trailing 12-Months
Company Description
Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
NUVB Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a number of strong clinical and commercial progress points — U.S. approval of IBTROZI, rapid new patient starts (~6x faster vs. prior launches), compelling durability data (median DOR 50 months in TKI‑naive), broad payer access, strong cash position ($529.2M), and advancing pipeline programs (safusidenib Phase III initiation and a non‑pivotal cohort with potential accelerated pathway). Offsetting these positives are near‑term commercial headwinds: a mismatch between new patient starts and net product revenue due to an early mix skewed toward later‑line patients who discontinue quickly, rising gross‑to‑net (~25%), high operating costs (R&D $115.1M; SG&A $151.6M), a discontinued DDC candidate, and long timelines for pivotal readouts (safusidenib SIGMA readout expected 2029). Overall, the call projects long‑term upside driven by clinical differentiation and international partnerships while acknowledging short‑term revenue and execution uncertainties.View all NUVB earnings summariesNUVB Stock 12 Month Forecast
Average Price Target
$12.00
▲(105.48% Upside)
Technical Analysis
Nektar Therapeutics
―
Precigen
―
Wave Life Sciences
―
Enliven Therapeutics
―
Praxis Precision Medicines
―
Ownership Overview
17.60% Insiders
16.24% Mutual Funds
9.17% Other Institutional Investors
47.53% Public Companies and Individual Investors